Buscar
01/10/2024
CLINICAL EXPERIENCE IN THE USE OF MESENCHYMAL STROMAL CELLS IN PEDIATRIC GRAFT-VERSUS-HOST DISEASE: ON BEHALF OF THE SPANISH GROUP OF STEM CELL TRANSPLANTATION (GETH)
Parente, CE, S nchez, DB, Angulo, BM, Carabante, MIB, Torija, IL, Trabazo, M, Fuentes, C, Plaza, M, Mart nez, AP, Urtasun, A, Riesco, S, Mu z, SG, Vinagre, S, de Heredia, CD, Marsal, J, Gonz lez-Vicent, M, P rez-Mart nez, A. CLINICAL EXPERIENCE IN THE USE OF MESENCHYMAL STROMAL CELLS IN PEDIATRIC GRAFT-VERSUS-HOST DISEASE: ON BEHALF OF THE SPANISH GROUP OF STEM CELL TRANSPLANTATION (GETH). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
UNRELATED DONOR TRANSPLANTATION OFFERS A REAL CURATIVE OPPORTUNITY FOR PATIENTS WITH TRANSFUSIONDEPENDENT THALASSAEMIA. EXPERIENCE OF THE SPANISH GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETH-TC)
Carabante, MIB, Men rguez, A, Bieler, CB, Garc a, LA, Oficialdegui, MLU, Panesso, M, Fornieles, MP, Fuentes, C, Enr quez, SV, Silva, GG, Duarte, ML, Hurtado, JMP, Torrent, M, Rubio, CDD. UNRELATED DONOR TRANSPLANTATION OFFERS A REAL CURATIVE OPPORTUNITY FOR PATIENTS WITH TRANSFUSIONDEPENDENT THALASSAEMIA. EXPERIENCE OF THE SPANISH GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
USE OF LETERMOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP
Kleinschmidt, K, Lucchini, G, Galimard, JE, Balduzzi, A, Czyzewski, K, Fraczkiewicz, J, Tambaro, FP, Adamcakova, J, Urtasun, A, Woelfl, M, Bernardo, ME, Biffi, A, Kriv n, G, Torija, IL, Sedlacek, P, Holter, W, Diesch, T, Albert, MH, Sobkowiak-Sobierajska, A, Vicent, MG, Ince, E, Johnson, SM, Meisel, R, Dalissier, A, Corbacioglu, S, Neven, B, Kalwak, K. USE OF LETERMOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
Hemodynamic monitoring and echocardiographic evaluation in cardiogenic shock
Ochagavía, A, Palomo-López, N, Fraile, V, Zapata, L. Hemodynamic monitoring and echocardiographic evaluation in cardiogenic shock. Medicina Intensiva. 2024; 48(10)DOI:10.1016/j.medin.2024.05.011. PMID:39097480. IF:3.100(Q2/3D).
01/10/2024
DEVELOPMENT AND CLINICAL VALIDATION OF LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY FOR INDIVIDUALIZED RUXOLITINIB ADJUSTMENT IN FUTURE CASES OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE
Redondo, S, Costa, M, Moreno-Martinez, ME, Riba, M, Aso, O, Iranzo, E, Esquirol, A, Sierra, J, Briones, J, Martino, R, Zapico, E, Garcia-Cadenas, I. DEVELOPMENT AND CLINICAL VALIDATION OF LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY FOR INDIVIDUALIZED RUXOLITINIB ADJUSTMENT IN FUTURE CASES OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING
Redondo, S, Arrufat, A, Esquirol, A, Saavedra, S, Arguello-Tomas, M, Caballero, AC, O ate, G, Garrido, A, Lopez, J, Miqueleiz, S, Portos, JM, Iranzo, E, Moreno-Martinez, ME, Riba, M, Sierra, J, Briones, J, Garc a-Cadenas, I, Martino, R. EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
EVALUATION OF MENTAL HEALTH THROUGH AN EHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY): DESCRIPTIVE ANALYSIS
Tobajas, E, Carretero, G, De Dios, A, Redondo, S, Vallv , M, Esquirol, A, Aso, O, Triquell, M, Moreno-Martinez, ME, Riba, M, Blasco, A, Martino, R, Gomis-Pastor, M, Garc a-Cadenas, I. EVALUATION OF MENTAL HEALTH THROUGH AN EHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY): DESCRIPTIVE ANALYSIS. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL
Redondo, S, De Dios, A, Vallve, M, Real, J, Triquell, M, Aso, O, Esquirol, A, Moreno-Martinez, M, Riba, M, Ruiz, J, Tobajas, E, Sierra, J, Briones, J, Martino, R, Gomis-Pastor, M, Garcia-Cadenas, I. MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).